Aliases & Classifications for Hypoxia

MalaCards integrated aliases for Hypoxia:

Name: Hypoxia 54 73

External Ids:

UMLS 73 C0242184

Summaries for Hypoxia

Novus Biologicals : 56 Hypoxia is a pathological condition in which the body as a whole (generalized hypoxia) or region of the body (tissue hypoxia) is deprived of adequate oxygen supply. Hypoxia contributes significantly to the pathophysiology of major categories of human disease, including myocardial and cerebral ischemia, cancer, pulmonary hypertension, congenital heart disease and chronic obstructive pulmonary disease. Hypoxia inducible factor-1 (HIF-1) is a transcription factor that regulates adaptive responses to a lack of oxygen in mammalian cells. HIF-1 consists of two proteins, HIF-1 alpha and HIF-1 beta. HIF-1 alpha accumulates under hypoxic conditions whereas HIF-1 beta is constitutively expressed. HIF-1 alpha is an important mediator of the hypoxic response of tumor cells and controls the up-regulation of a number of factors important for solid tumor expansion including the angiogenic factor VEGF.

MalaCards based summary : Hypoxia is related to acute mountain sickness and renal cell carcinoma, nonpapillary, and has symptoms including seizures, fever and dyspnea. An important gene associated with Hypoxia is KMT2A (Lysine Methyltransferase 2A), and among its related pathways/superpathways are CDK-mediated phosphorylation and removal of Cdc6 and Cellular Senescence (REACTOME). The drugs Bosentan and Sevoflurane have been mentioned in the context of this disorder. Affiliated tissues include endothelial, brain and lung, and related phenotypes are Decreased viability and Decreased viability

NINDS : 54 Cerebral hypoxia refers to a condition in which there is a decrease of oxygen supply to the brain even though there is adequate blood flow. Drowning, strangling, choking, suffocation, cardiac arrest, head trauma, carbon monoxide poisoning, and complications of general anesthesia can create conditions that can lead to cerebral hypoxia. Symptoms of mild cerebral hypoxia include inattentiveness, poor judgment, memory loss, and a decrease in motor coordination. Brain cells are extremely sensitive to oxygen deprivation and can begin to die within five minutes after oxygen supply has been cut off. When hypoxia lasts for longer periods of time, it can cause coma, seizures, and even brain death.  In brain death, there is no measurable activity in the brain, although cardiovascular function is preserved. Life support is required for respiration.

Wikipedia : 76 Hypoxia is a condition in which the body or a region of the body is deprived of adequate oxygen supply... more...

Related Diseases for Hypoxia

Diseases related to Hypoxia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 671)
# Related Disease Score Top Affiliating Genes
1 acute mountain sickness 30.8 EGLN1 HIF1A HIF1AN VHL
2 renal cell carcinoma, nonpapillary 30.6 EPAS1 HIF1A HIF1AN MTOR VHL
3 polycythemia 30.3 EGLN1 EPAS1 HIF1A VHL
4 clear cell renal cell carcinoma 30.3 EPAS1 HIF1A MTOR VHL
5 kidney cancer 30.2 HIF1A MTOR VHL
6 erythrocytosis, familial, 2 29.7 EGLN1 EPAS1 HIF1A VHL
7 fumarate hydratase deficiency 29.6 HIF1A VHL
8 retinal hemangioblastoma 29.4 EPAS1 HIF1A VHL
9 cerebral hypoxia 12.6
10 respiratory underresponsiveness to hypoxia and hypercapnia 12.0
11 polycythemia due to hypoxia 12.0
12 neonatal hypoxic and ischemic brain injury 11.5
13 exudative vitreoretinopathy 1 11.4
14 pulmonary edema 11.3
15 brain ischemia 11.3
16 chronic mountain sickness 11.3
17 apnea of prematurity 11.3
18 methemoglobinemia 11.3
19 tempi syndrome 11.2
20 asphyxia neonatorum 11.2
21 methemoglobinemia due to deficiency of methemoglobin reductase 11.1
22 pneumothorax, primary spontaneous 10.9
23 methemoglobinemia and ambiguous genitalia 10.9
24 exudative vitreoretinopathy 2, x-linked 10.9
25 exudative vitreoretinopathy 4 10.9
26 telangiectasia, hereditary hemorrhagic, type 4 10.9
27 exudative vitreoretinopathy 5 10.9
28 exudative vitreoretinopathy 6 10.9
29 exudative vitreoretinopathy 7 10.9
30 leukostasis 10.9
31 hantavirus pulmonary syndrome 10.9
32 severe acute respiratory syndrome 10.9
33 congenital laryngeal palsy 10.9
34 typical congenital nemaline myopathy 10.9
35 lung cancer susceptibility 3 10.7
36 ischemia 10.7
37 polycystic kidney disease 10.6
38 pulmonary hypertension 10.5
39 breast cancer 10.5
40 hepatocellular carcinoma 10.5
41 lung cancer 10.5
42 prostate cancer 10.5
43 squamous cell carcinoma 10.4
44 pancreatic cancer 10.4
45 glioma 10.4
46 glioblastoma 10.4
47 colorectal cancer 10.4
48 melanoma 10.4
49 small cell cancer of the lung 10.4
50 neuroblastoma 10.4

Graphical network of the top 20 diseases related to Hypoxia:



Diseases related to Hypoxia

Symptoms & Phenotypes for Hypoxia

UMLS symptoms related to Hypoxia:


seizures, fever, dyspnea, edema, apnea, cachexia, vertigo, hemoptysis, headache, syncope, cyanosis, chills, coughing, hoarseness, increased sweating, icterus, signs and symptoms, signs and symptoms, digestive, hot flushes, cheyne-stokes respiration, sneezing, signs and symptoms, respiratory, anoxemia, hyperoxia, motor symptom, skin symptoms, physical symptom, physical appearance, body

GenomeRNAi Phenotypes related to Hypoxia according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.21 MTOR
2 Decreased viability GR00221-A-1 10.21 MTOR VHL
3 Decreased viability GR00221-A-2 10.21 EGLN3 EP300 VHL
4 Decreased viability GR00221-A-4 10.21 MTOR
5 Decreased viability GR00240-S-1 10.21 PSMA7
6 Decreased viability GR00301-A 10.21 EGLN3 VHL
7 Decreased viability GR00342-S-1 10.21 MTOR
8 Decreased viability GR00342-S-2 10.21 MTOR
9 Decreased viability GR00381-A-1 10.21 EGLN2 EGLN3 HIF1AN PSMA7
10 Decreased viability GR00402-S-2 10.21 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
11 no effect GR00402-S-1 9.62 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300

MGI Mouse Phenotypes related to Hypoxia:

46 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.45 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
2 homeostasis/metabolism MP:0005376 10.39 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
3 cellular MP:0005384 10.38 ARNT EGLN1 EGLN2 EGLN3 EP300 HIF1A
4 growth/size/body region MP:0005378 10.35 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
5 hematopoietic system MP:0005397 10.34 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
6 embryo MP:0005380 10.33 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
7 immune system MP:0005387 10.27 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
8 mortality/aging MP:0010768 10.25 ARNT CITED2 EGLN1 EGLN3 EP300 EPAS1
9 craniofacial MP:0005382 10.21 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
10 muscle MP:0005369 10.18 EGLN1 EGLN2 EGLN3 EP300 EPAS1 HIF1A
11 liver/biliary system MP:0005370 10.11 ARNT EGLN1 EGLN2 EGLN3 EPAS1 HIF1A
12 nervous system MP:0003631 10.06 ARNT CITED2 EGLN1 EGLN3 EP300 EPAS1
13 limbs/digits/tail MP:0005371 10.02 CITED2 EGLN2 EGLN3 HIF1A KMT2A REST
14 normal MP:0002873 9.91 ARNT CITED2 EGLN3 EP300 HIF1A HIF1AN
15 neoplasm MP:0002006 9.85 ARNT EP300 HIF1A KMT2A TIGAR VHL
16 renal/urinary system MP:0005367 9.81 ARNT CITED2 EGLN1 EP300 HIF1A KMT2A
17 respiratory system MP:0005388 9.56 CITED2 EGLN1 EP300 EPAS1 HIF1A HIF1AN
18 vision/eye MP:0005391 9.23 CITED2 EGLN3 EP300 EPAS1 HIF1A P4HTM

Drugs & Therapeutics for Hypoxia

Drugs for Hypoxia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 709)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bosentan Approved, Investigational Phase 4,Phase 1 147536-97-8 104865
2
Sevoflurane Approved, Vet_approved Phase 4,Not Applicable 28523-86-6 5206
3
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 437-38-7 3345
4
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 2078-54-8 4943
5
Sufentanil Approved, Investigational Phase 4,Not Applicable 56030-54-7 41693
6
Racepinephrine Approved Phase 4,Phase 2,Phase 3,Not Applicable 329-65-7 838
7
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 51-43-4 5816
8
Bromhexine Approved Phase 4 3572-43-8
9
Valproic Acid Approved, Investigational Phase 4,Not Applicable 99-66-1 3121
10
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
11
Ranolazine Approved, Investigational Phase 4 142387-99-3, 95635-55-5 56959
12
Dopamine Approved Phase 4,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
13
Levodopa Approved Phase 4 59-92-7 6047
14
Metformin Approved Phase 4,Phase 2,Phase 1,Not Applicable 657-24-9 14219 4091
15
Remifentanil Approved Phase 4,Not Applicable 132875-61-7 60815
16
Atropine Approved, Vet_approved Phase 4 51-55-8, 5908-99-6 174174
17
Succinylcholine Approved Phase 4 306-40-1 5314
18
Ipratropium Approved Phase 4 60205-81-4, 22254-24-6 43232
19
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
20
Terbutaline Approved Phase 4 23031-25-6 5403
21
Budesonide Approved Phase 4,Phase 3,Phase 1 51333-22-3 63006 5281004
22
Acetazolamide Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 59-66-5 1986
23
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 113775-47-6 68602 5311068
24
Tocopherol Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 1406-66-2 14986
25
Midazolam Approved, Illicit Phase 4,Phase 3,Phase 2,Not Applicable 59467-70-8 4192
26
Metoprolol Approved, Investigational Phase 4,Phase 2,Phase 3 37350-58-6, 51384-51-1 4171
27
Adenosine Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 58-61-7 60961
28
Zinc Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 7440-66-6
29
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 7487-88-9 24083
30
Nitric Oxide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 10102-43-9 145068
31 tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
33
Ibuprofen Approved Phase 4,Phase 2,Phase 1,Not Applicable 15687-27-1 3672
34
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 93-14-1 3516
35
Amlodipine Approved Phase 4,Phase 2,Phase 3 88150-42-9 2162
36
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 616-91-1 12035
37
Methazolamide Approved Phase 4,Phase 1,Phase 2 554-57-4 4100
38
Alprostadil Approved, Investigational Phase 4,Not Applicable 745-65-3 149351 5280723
39
Nebivolol Approved, Investigational Phase 4 99200-09-6, 152520-56-4, 118457-14-0 71301
40
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
41
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
42
Bisoprolol Approved Phase 4 66722-44-9 2405
43
Doxapram Approved, Vet_approved Phase 4 309-29-5 3156
44
Etomidate Approved Phase 4 33125-97-2 667484 36339
45
Meperidine Approved Phase 4,Phase 2 57-42-1 4058
46
Dutasteride Approved, Investigational Phase 4 164656-23-9 6918296 152945
47
Ketamine Approved, Vet_approved Phase 4,Not Applicable 6740-88-1 3821
48
Indomethacin Approved, Investigational Phase 4,Phase 1,Phase 2 53-86-1 3715
49
Nicorandil Approved, Investigational Phase 4 65141-46-0 47528
50
Captopril Approved Phase 4 62571-86-2 44093

Interventional clinical trials:

(show top 50) (show all 1612)
# Name Status NCT ID Phase Drugs
1 Comparison of Efficacy Different Treatment Regimens in Pulmonary Hypertension Secondary to Lung Disease and or Hypoxia Unknown status NCT01449253 Phase 4 Sildenafil;Bosentan
2 Sevoflurane Decreases the Risk of Postoperative Delirium After Cerebral Hypoxemia During Surgery Unknown status NCT02133638 Phase 4 Sevoflurane;Propofol
3 Continuous Intravenous Sufentanil Infusion for Postoperative Pain Management Following Tonsillectomy or Adeno-tonsillectomy in Children Unknown status NCT02205580 Phase 4 continuous intravenous sufentanil 0.02μg•kg-1•h-1 infusion;continuous intravenous sufentanil 0.03μg•kg-1•h-1 infusion;continuous intravenous sufentanil 0.04μg•kg-1•h-1 infusion
4 Sodium Bicarbonate in Cardiopulmonary Resuscitation Unknown status NCT01377337 Phase 4 sodium bicarbonate
5 Postpartum Oxygen Inhalation for the Treatment of Postpartum Haemorrhage Unknown status NCT01180192 Phase 4 oxygen
6 Home Oxygen Therapy in Bronchiolitis Unknown status NCT01216553 Phase 4
7 Effect of Acute Hyperglycemia on Renal Tissue Oxygenation Unknown status NCT02346149 Phase 4
8 The Benefit of Prophylactic Anticonvulsant in Post Cardiac Arrest Syndrome With Induced Mild Hypothermia Unknown status NCT01083784 Phase 4 Use of prophylactic anticonvulsants (valproate, clonazepam);Control group
9 CPAP in Liver Transplant Unknown status NCT00510770 Phase 4
10 Ranolazine a Potential New Therapeutic Application Unknown status NCT02687269 Phase 4 Ranolazine;Placebo
11 Dopamine Treatment in Children With Cerebral Palsy With Dystonia- A Double Blind Controlled Study Unknown status NCT01361373 Phase 4 L- DOPA;placebo
12 Metformin for Weight Control in Adolescents Taking Atypical Antipsychotics Unknown status NCT00845936 Phase 4 Metformin
13 The Effect on the Older's Cognition of Dual-loop Target Controlled Infusion Guided by Narcotrend Index Unknown status NCT03010098 Phase 4
14 Atropine Versus no Atropine for Neonatal Rapid Sequence Intubation Unknown status NCT01595399 Phase 4 atropine;Placebo
15 LTOT in COPD Patients With Moderate Chronic Hypoxemia and Chronic Heart Failure Unknown status NCT00668408 Phase 4
16 AZ, MZ, and the Pulmonary System Response to Hypoxia Completed NCT02760121 Phase 4 Acetazolamide;Methazolamide;Placebo
17 Acute Ventilatory Response to Hypoxia During Sedation With Dexmedetomidine Compared to Propofol in Healthy Male Volunteers Completed NCT01873612 Phase 4
18 Hypoxic Pulmonary Vasoconstriction Pilot Study Completed NCT03733470 Phase 4 Hypoxia Administration study group;Hyperoxia Administration study group;Sildenafil study group
19 5-hydroxytryptophan and Creatine for Treatment Resistant Depression Associated With Hypoxia in Females Completed NCT02356107 Phase 4 5-hydroxytryptophan and Creatine monohydrate
20 Effect of Systemic Hypoxia and Hyperoxia on Retinal Oxygen Saturation Completed NCT01692821 Phase 4 100% oxygen breathing;15% oxygen in N2 breathing;12% oxygen in N2 breathing
21 Neuroimaging During Pure Oxygen Breathing Completed NCT03268590 Phase 4 Oxygen
22 Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients With Diabetic Nephropathy Completed NCT02628106 Phase 4 Lipo-PGE1
23 Effects of Nebivolol Versus Carvedilol on Cardiopulmonary Function at High Altitude in Healthy Subjects. Completed NCT00924833 Phase 4 placebo;Carvedilol;Nebivolol
24 Effect of Neuromuscular Blockade and Reversal on Breathing Completed NCT02845375 Phase 4 Sugammadex;Neostigmine;Placebo
25 Muscle Fatigue and Carbonic Anhydrase Inhibitors Completed NCT02758470 Phase 4 Acetazolamide;Methazolamide
26 CPAP in SAHS Patients With Hypertension Completed NCT02398032 Phase 4
27 Nebivolol Versus Bisoprolol Versus Carvedilol in Heart Failure Completed NCT00517725 Phase 4 carvedilol;bisoprolol;Nebivolol
28 Single High Dose Vitamin C, E in Severe Birth Asphyxia Completed NCT01743742 Phase 4 Vitamin E, Vitamin C
29 Ambulatory Oxygen Effects on Muscles in COPD Completed NCT01722370 Phase 4 Oxygen;Medical air equivalent
30 Doxapram as an Additive to Propofol Sedation in Sedation for ERCP Completed NCT02171910 Phase 4 Doxapram;Placebo
31 Etomidate vs. Midazolam for Sedation During ERCP Completed NCT02027311 Phase 4 Etomidate;Midazolam;Meperidine
32 The Effect of Nasal Cannula During the First 2 Hours Postoperative in Patient Undergoing Thoracotomy Completed NCT01725464 Phase 4
33 Effect of Dutasteride on HIF-1alpha and VEGF in the Prostate Completed NCT00880672 Phase 4 dutasteride
34 Safety Study of Analgesia After Craniotomy Surgery With End Tidal (ET) Carbon Dioxide (CO2) Monitoring Completed NCT01327677 Phase 4 Fentanyl;Fentanyl
35 Randomized Clinical Trial of Propofol, 1:1 and 4:1 Combination of Propofol and Ketamine for Procedural Sedation Completed NCT01260662 Phase 4 Propofol;1:1 Propofol/Ketamine;4:1 Propofol/Ketamine
36 Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude Completed NCT00714740 Phase 4 acetazolamide
37 Propofol-Ketamine vs Remifentanyl-Ketamine for Sedation in Pediatric Patients Undergoing Colonoscopy Completed NCT02602743 Phase 4 Remifentanyl;Propofol;Ketamine
38 Cerebral Blood Flow and PETCO2 on Neuromuscular Function During Environmental Stress Completed NCT01830335 Phase 4 Indomethacin;Placebo
39 The Use of Statins for Myocardial Death Prevention Completed NCT00772564 Phase 4 Atorvastatin
40 Vasoactive Hormones During the Night in Patients With Obstructive Sleep Apnea Before and After Treatment With CPAP. Completed NCT00360659 Phase 4
41 Preventive Effect of the PRetreatment With Intravenous Nicorandil on Contrast-Induced Nephropathy in Patients With RenaL Dysfunction UndEergoing Coronary Angiography (PRINCIPLE Study) Completed NCT01103336 Phase 4 pretreatment with intravenous nicorandil vs. placebo before coronary angiography
42 Efficacy Study of Riociguat and Its Effects on Exercise Performance and Pulmonary Artery Pressure at High Altitude Completed NCT02024386 Phase 4 Riociguat
43 Increased Renal Oxygenation and Angiotensin Converting Enzyme Inhibition Completed NCT01545479 Phase 4 captopril 25mg
44 Ranibizumab in Patients With Branch Retinal Vein Occlusion Completed NCT01027481 Phase 4 Lucentis
45 Effect Of Ketamine Infusion In Patients With COPD Applied One Lung Ventilation Completed NCT02962999 Phase 4 Ketamine;Saline
46 Influence of Cardiopulmonary Bypass, and Sevoflurane or Propofol Anesthesia, on Tissue Oxygen Saturation. Completed NCT02593448 Phase 4
47 To Evaluate the Effect of Chlorhexidine-benzidamine Administration Completed NCT03253497 Phase 4 Chlorobenzene Liquid
48 The Effects of Oral Dipyridamole Treatment on the Innate Immune Response During Human Endotoxemia Completed NCT01091571 Phase 4 Dipyridamole;Placebo
49 The Correlations Between Early Enteral Nutrition and Intra-abdominal Pressure in Severe Acute Pancreatitis Completed NCT01507766 Phase 4 early enteral nutrition;Delayed enteral nutrition
50 Erythropoietin in the Prevention of Acute Mountain Sickness Completed NCT01665781 Phase 4 Erythropoietin

Search NIH Clinical Center for Hypoxia

Genetic Tests for Hypoxia

Anatomical Context for Hypoxia

MalaCards organs/tissues related to Hypoxia:

41
Endothelial, Brain, Lung, Breast, Prostate, Heart, Kidney

Publications for Hypoxia

Articles related to Hypoxia:

(show top 50) (show all 8705)
# Title Authors Year
1
Knockdown of USP28 enhances the radiosensitivity of esophageal cancer cells via the c-Myc/hypoxia-inducible factor-1 alpha pathway. ( 30206969 )
2019
2
Hypoxia induced δ-Catenin to enhance mice hepatocellular carcinoma progression via Wnt signaling. ( 30458179 )
2019
3
Curcumin pretreatment protects against hypoxia/reoxgenation injury via improvement of mitochondrial function, destabilization of HIF-1α and activation of Epac1-Akt pathway in rat bone marrow mesenchymal stem cells. ( 30551377 )
2019
4
Moringa oleifera extract attenuates the CoCl2 induced hypoxia of rat's brain: Expression pattern of HIF-1α, NF-kB, MAO and EPO. ( 30551423 )
2019
5
MicroRNA-150 relieves vascular remodeling and fibrosis in hypoxia-induced pulmonary hypertension. ( 30551428 )
2019
6
Isosteviol Sodium Protects Neural Cells Against Hypoxia-Induced Apoptosis Through Inhibiting MAPK and NF-κB Pathways. ( 30539754 )
2019
7
Hypoxia imaging with [18F]HX4 PET in squamous cell head and neck cancers: a pilot study for integration into treatment planning. ( 30371605 )
2019
8
Antioxidative effects of flavonoids and their metabolites against hypoxia/reoxygenation-induced oxidative stress in a human first trimester trophoblast cell line. ( 30309520 )
2019
9
Protective effects of lncRNA H19 silence against hypoxia-induced injury in PC-12 cells by regulating miR-28. ( 30312698 )
2019
10
Hypoxia increases chemoresistance in human medulloblastoma DAOY cells via hypoxia‑inducible factor 1α‑mediated downregulation of the CYP2B6, CYP3A4 and CYP3A5 enzymes and inhibition of cell proliferation. ( 30320358 )
2019
11
Cardioprotective effects of alternagin-C (ALT-C), a disintegrin-like protein from Rhinocerophis alternatus snake venom, on hypoxia-reoxygenation-induced injury in fish. ( 30352307 )
2019
12
Mathematical modelling of a hypoxia-regulated oncolytic virus delivered by tumour-associated macrophages. ( 30359572 )
2019
13
RGS5 decreases the proliferation of human ovarian carcinoma‑derived primary endothelial cells through the MAPK/ERK signaling pathway in hypoxia. ( 30365142 )
2019
14
Rutin alleviates hypoxia/reoxygenation-induced injury in myocardial cells by up-regulating SIRT1 expression. ( 30365940 )
2019
15
Nitric oxide inhibits hypoxia-induced impairment of human RBC deformability through reducing the cross-linking of membrane protein band 3. ( 30218451 )
2019
16
Effects of regional hypoxia and incubation temperature on growth, differentiation, heart mass, and oxygen consumption in embryos of the leopard gecko (Eublepharis macularius). ( 30240787 )
2019
17
ESM-1 promotes adhesion between monocytes and endothelial cells under intermittent hypoxia. ( 30144067 )
2019
18
Paracrine potential of adipose stromal vascular fraction cells to recover hypoxia-induced loss of cardiomyocyte function. ( 30171703 )
2019
19
Assessment of muscular energy metabolism and heat shock response of the green abalone Haliotis fulgens (Gastropoda: Philipi) at extreme temperatures combined with acute hypoxia and hypercapnia. ( 30195088 )
2019
20
H2S mediates carotid body response to hypoxia but not anoxia. ( 30086385 )
2019
21
Deletion of long noncoding RNA EFNA3 aggravates hypoxia-induced injury in PC-12 cells by upregulation of miR-101a. ( 30125989 )
2019
22
Long-term exposure to high altitude hypoxia during pregnancy increases fetal heart susceptibility to ischemia/reperfusion injury and cardiac dysfunction. ( 30017521 )
2019
23
Stabilization of p22phox by Hypoxia Promotes Pulmonary Hypertension. ( 30044141 )
2019
24
Hypoxia-inducible factor-1 (HIF-1) activation in myeloid cells accelerates DSS-induced colitis progression in mice. ( 29967068 )
2018
25
Retinoic acid receptor-related orphan receptor RORI+ regulates differentiation and survival of keratinocytes during hypoxia. ( 28332183 )
2018
26
Nocturnal cerebral hypoxia in obstructive sleep apnoea: a randomised controlled trial. ( 29700104 )
2018
27
The role of the ATPase inhibitor factor 1 (IF<sub>1</sub>) in cancer cells adaptation to hypoxia and anoxia. ( 29097244 )
2018
28
ERK1/2 and Akt phosphorylation were essential for MGF E peptide regulating cell morphology and mobility but not proangiogenic capacity of BMSCs under severe hypoxia. ( 29441602 )
2018
29
Role of hypoxia-inducible factor-1 in the development of renal fibrosis in mouse obstructed kidney: Special references to HIF-1 dependent gene expression of profibrogenic molecules. ( 29352658 )
2018
30
Tibial dyschondroplasia is closely related to suppression of expression of hypoxia-inducible factors 1I+, 2I+, and 3I+ in chickens. ( 28693310 )
2018
31
Hypoxia-Induced Signaling Activation in Neurodegenerative Diseases: Targets for New Therapeutic Strategies. ( 29439330 )
2018
32
Intermittent hypoxia promotes melanoma lung metastasis via oxidative stress and inflammation responses in a mouse model of obstructive sleep apnea. ( 29433520 )
2018
33
Twist1 in Hypoxia-induced Pulmonary Hypertension through Transforming Growth Factor-I^-Smad Signaling. ( 28915063 )
2018
34
Glycolysis gatekeeper PDK1 reprograms breast cancer stem cells under hypoxia. ( 29251717 )
2018
35
FAT10 attenuates hypoxia-induced cardiomyocyte apoptosis by stabilizing caveolin-3. ( 29438664 )
2018
36
Hypoxia and myelination deficits in the developing brain. ( 29964158 )
2018
37
LncRNA TUG1 serves an important role in hypoxia-induced myocardial cell injury by regulating the miRa89145a895pa89Binp3 axis. ( 29207102 )
2018
38
Hypoxia induces production of citrullinated proteins in human fibroblast-like synoviocytes through regulating HIF1I+. ( 29484680 )
2018
39
Combined fetal inflammation and postnatal hypoxia causes myelin deficits and autism-like behavior in a rat model of diffuse white matter injury. ( 28925578 )
2018
40
Tissue-penetrating, hypoxia-responsive echogenic polymersomes for drug delivery to solid tumors. ( 29968262 )
2018
41
Yap-Hippo pathway regulates cerebral hypoxia-reoxygenation injury in neuroblastoma N2a cells via inhibiting ROCK1/F-actin/mitochondrial fission pathways. ( 29796942 )
2018
42
Multiple myeloma cells adapted to long-exposure of hypoxia exhibit stem cell characters with TGF-I^/Smad pathway activation. ( 29309790 )
2018
43
Hypoxia-inducible transcription factors in fish: expression, function and interconnection with the circadian clock. ( 29973414 )
2018
44
Hypoxia exposure induced cisplatin resistance partially via activating p53 and hypoxia inducible factor-1I+ in non-small cell lung cancer A549 cells. ( 29971135 )
2018
45
Hypoxia promotes breast cancer cell invasion through HIF-1I+-mediated up-regulation of the invadopodial actin bundling protein CSRP2. ( 29976963 )
2018
46
Deregulation of Hexokinase II Is Associated with Glycolysis, Autophagy, and the Epithelial-Mesenchymal Transition in Tongue Squamous Cell Carcinoma under Hypoxia. ( 29682563 )
2018
47
Chronic intermittent hypoxia promotes myocardial ischemia-related ventricular arrhythmias and sudden cardiac death. ( 29445096 )
2018
48
Retroperitoneal paraganglioma in a patient with Fontan: The hypoxia connection. ( 29922019 )
2018
49
Silencing of NADPH oxidase 4 attenuates hypoxia resistance in neuroblastoma cells SHSY-5Y by inhibiting PI3K/Akt-dependent glycolysis. ( 29426376 )
2018
50
TGF-b1 or Hypoxia Enhance Glucose Metabolism and Lactate Production via HIF1A Signaling in Tendon Cells. ( 29447016 )
2018

Variations for Hypoxia

Expression for Hypoxia

Search GEO for disease gene expression data for Hypoxia.

Pathways for Hypoxia

Pathways related to Hypoxia according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.2 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
2
Show member pathways
12.95 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
3 12.83 ARNT EGLN1 EGLN2 EGLN3 EP300 EPAS1
4
Show member pathways
12.47 ARNT EGLN1 EGLN2 EGLN3 EP300 EPAS1
5 12.24 ARNT EGLN1 EPAS1 HIF1A HIF1AN MTOR
6 11.92 ARNT EGLN1 EGLN2 EGLN3 EP300 HIF1A
7 11.84 ARNT EGLN1 EP300 HIF1A HIF1AN
8 11.82 EP300 HIF1A MTOR
9
Show member pathways
11.79 ARNT EPAS1 HIF1A VHL
10 11.72 ARNT CITED2 EGLN1 EGLN3 EP300 HIF1A
11
Show member pathways
11.58 ARNT EP300 HIF1A
12 11.54 HIF1A MTOR TIGAR
13 11.39 ARNT EP300 HIF1A
14 11.38 ARNT EGLN1 HIF1A HIF1AN
15
Show member pathways
11.36 ARNT CITED2 EGLN3 EP300 EPAS1 HIF1A
16 11.14 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
17 10.98 ARNT HIF1A HIF1AN HIF3A VHL
18 10.96 ARNT EGLN1 EGLN2 EP300 HIF1A HIF1AN
19 10.81 EPAS1 VHL
20 10.52 HIF1A HIF1AN

GO Terms for Hypoxia

Cellular components related to Hypoxia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.86 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
2 protein-containing complex GO:0032991 9.72 CITED2 EP300 HIF1A HIGD1A MTOR
3 transcription factor complex GO:0005667 9.56 ARNT EP300 EPAS1 HIF1A
4 nucleoplasm GO:0005654 9.53 ARNT CITED2 EGLN2 EGLN3 EP300 EPAS1
5 cytosol GO:0005829 10 EGLN1 EGLN3 EP300 EPAS1 HIF1A HIF1AN

Biological processes related to Hypoxia according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.97 CITED2 HIF1A HIGD1A HYOU1 VHL
2 post-translational protein modification GO:0043687 9.91 EPAS1 HIF1A HIF3A PSMA7 VHL
3 negative regulation of gene expression GO:0010629 9.87 CITED2 HIF1A REST VHL
4 positive regulation of endothelial cell proliferation GO:0001938 9.73 ARNT HIF1A MTOR
5 cellular response to hypoxia GO:0071456 9.7 EPAS1 HIF1A HIGD1A HILPDA HYOU1 MTOR
6 regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061418 9.7 ARNT EGLN1 EGLN2 EGLN3 EP300 EPAS1
7 embryonic placenta development GO:0001892 9.62 ARNT CITED2 EPAS1 HIF1A
8 negative regulation of reactive oxygen species metabolic process GO:2000378 9.61 HIF1A TIGAR
9 positive regulation of glycolytic process GO:0045821 9.61 ARNT HIF1A
10 mRNA transcription by RNA polymerase II GO:0042789 9.6 ARNT HIF1A
11 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.59 ARNT HIF1A
12 embryonic hemopoiesis GO:0035162 9.58 HIF1A KMT2A
13 regulation of transcription from RNA polymerase II promoter in response to oxidative stress GO:0043619 9.58 ARNT EPAS1 HIF1A
14 peptidyl-proline hydroxylation to 4-hydroxy-L-proline GO:0018401 9.56 EGLN1 EGLN2 EGLN3 P4HTM
15 oxygen homeostasis GO:0032364 9.54 EGLN1 HIF1A
16 negative regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061428 9.54 CITED2 HIF1AN VHL
17 positive regulation of hormone biosynthetic process GO:0046886 9.49 ARNT HIF1A
18 response to hypoxia GO:0001666 9.32 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
19 regulation of transcription, DNA-templated GO:0006355 10.13 ARNT CITED2 EP300 EPAS1 HIF1A HIF3A
20 positive regulation of transcription by RNA polymerase II GO:0045944 10.09 ARNT CITED2 EGLN1 EP300 EPAS1 HIF1A
21 oxidation-reduction process GO:0055114 10.02 EGLN1 EGLN2 EGLN3 HIF1AN HIGD1A P4HTM
22 transcription by RNA polymerase II GO:0006366 10 EP300 EPAS1 HIF1A HIF3A KMT2A REST
23 positive regulation of transcription, DNA-templated GO:0045893 10 ARNT CITED2 EP300 HIF1A KMT2A REST

Molecular functions related to Hypoxia according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.91 EGLN1 EGLN2 EGLN3 HIF1AN P4HTM
2 transcription factor binding GO:0008134 9.85 ARNT EP300 EPAS1 HIF1A REST VHL
3 protein dimerization activity GO:0046983 9.8 ARNT EPAS1 HIF1A HIF3A
4 iron ion binding GO:0005506 9.72 EGLN1 EGLN2 EGLN3 HIF1AN P4HTM
5 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.71 EGLN1 EGLN2 EGLN3 P4HTM
6 histone acetyltransferase binding GO:0035035 9.61 CITED2 EPAS1 HIF1A
7 dioxygenase activity GO:0051213 9.55 EGLN1 EGLN2 EGLN3 HIF1AN P4HTM
8 oxygen sensor activity GO:0019826 9.46 EGLN2 HIF1AN
9 peptidyl-proline 4-dioxygenase activity GO:0031545 9.43 EGLN1 EGLN2 EGLN3
10 L-ascorbic acid binding GO:0031418 9.26 EGLN1 EGLN2 EGLN3 P4HTM
11 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors GO:0016706 9.02 EGLN1 EGLN2 EGLN3 HIF1AN P4HTM
12 protein binding GO:0005515 10.43 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
13 DNA-binding transcription factor activity GO:0003700 10.02 ARNT CITED2 EPAS1 HIF1A HIF3A KMT2A

Sources for Hypoxia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30